Last update: Jan. 15, 2020

チニダゾール

Very Low Risk for breastfeeding


Safe. Compatible.
Minimal risk for breastfeeding and infant.

An antiprotozoal and antibacterial (anaerobic bacteria). Indicated in urogenital trichomoniasis, non-specific vaginitis, giardiasis, intestinal and hepatic amebiasis, acute ulcerative gingivitis and prophylaxis of postoperative infections by anaerobic bacteria.
Administered orally or intravenously in a single or daily dose for 3 to 6 days according to pathology.

It is excreted in breastmilk in clinically insignificant amounts (Evaldson 1985, Männistö 1983, Wood 1982), much lower than the dose prescribed to infants.

Its use is authorized in infants from one month old.

Some authors recommend waiting 3 days before breastfeeding again following administration (CDC 2010, Evaldson 1985). In the meantime, express and discard breastmilk regularly.

The possibility of transient gastroenteritis due to altered intestinal flora in infants whose mothers take antibiotics should be taken into account (Ito 1993).

It has very little plasma absorption when used topically, as a cream or vaginal ovules, so the amount excreted in milk is expected to be even less than following systemic administration.

Alternatives

Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

チニダゾール is Tinidazole in Japanese.

Is written in other languages:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 100 %
Molecular weight 247 daltons
Protein Binding 12 %
VD 0,8 l/Kg
Tmax 2 hours
T1/2 12 - 14 hours
M/P ratio 1,3 -
Theoretical Dose 0,87 - 1,91 mg/Kg/d
Relative Dose 2,6 - 5,7 %
Relat.Ped.Dose 1,2 - 3,8 %

References

  1. CDC - Workowski KA, Berman S; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep. 2010 Abstract Full text (link to original source) Full text (in our servers)
  2. Ito S, Blajchman A, Stephenson M, Eliopoulos C, Koren G. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. Am J Obstet Gynecol. 1993 May;168(5):1393-9. Abstract
  3. Evaldson GR, Lindgren S, Nord CE, Rane AT. Tinidazole milk excretion and pharmacokinetics in lactating women. Br J Clin Pharmacol. 1985 Abstract Full text (link to original source) Full text (in our servers)
  4. Roe FJ. Safety of nitroimidazoles. Scand J Infect Dis Suppl. 1985 Abstract
  5. Männistö PT, Karhunen M, Koskela O, Suikkari AM, Mattila J, Haataja H. Concentrations of tinidazole in breast milk. Acta Pharmacol Toxicol (Copenh). 1983 Abstract
  6. Chaikin P, Alton KB, Sampson C, Weintraub HS. Pharmacokinetics of tinidazole in male and female subjects. J Clin Pharmacol. 1982 Abstract
  7. Wood BA, Faulkner JK, Monro AM. The pharmacokinetics, metabolism and tissue distribution of tinidazole. J Antimicrob Chemother. 1982 Abstract
  8. Andersson KE. Pharmacokinetics of nitroimidazoles. Spectrum of adverse reactions. Scand J Infect Dis Suppl. 1981 Abstract
  9. Wood BA, Monro AM. Pharmacokinetics of tinidazole and metronidazole in women after single large oral doses. Br J Vener Dis. 1975 Abstract Full text (link to original source) Full text (in our servers)

Total visits

1,136

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write to us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana from Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM